VPML – Alligator Bioscience

2024-07-112024-07-11

Regulatory

Alligator Bioscience AB reports financial results for H1 2024 and Q2 2024 and provides a business update

Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase ...

2024-03-21

Regulatory

Lund, Sweden, March 21, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2023, as ...

2023-07-13

Regulatory

Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...

2023-03-24

Regulatory

Lund, Sweden, March 24, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2022 has been publi ...

2022-07-12

Regulatory

· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data be ...

2022-03-22

Regulatory

Lund, Sweden, March 22, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2021 has been publi ...

2022-02-112022-05-17

Regulatory

OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clini ...

2021-07-13

Regulatory

Positive Phase I data for ATOR-1017 ”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on ...

2019-07-11

Regulatory

Competitive safety data for ADC-1013. Significant events April-June• Janssen presented data from the clinical Phase I study with ADC-1013 in ...